Facioscapulohumeral Muscular Dystrophy (FSHD) Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)
Conditions: Facioscapulohumeral Muscular Dystrophy; Charcot-Marie-Tooth Disease Intervention: Drug: ACE-083 Sponsor: Acceleron Pharma, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 9, 2019 Category: Research Source Type: clinical trials
